March 8, 2022
Astellas Pharma said on March 7 that its nonhormonal agent fezolinetant yielded favorable results in an overseas PIII study for the treatment of moderate to severe vasomotor symptoms associated with menopause (VMS), commonly known as hot flashes and night sweats...read more